IntelliPharmaCeutics Intl (IPCI) Given a $3.00 Price Target at HC Wainwright

IntelliPharmaCeutics Intl (NASDAQ:IPCI) (TSE:I) has been given a $3.00 price target by equities research analysts at HC Wainwright in a research note issued on Monday. The brokerage currently has a “buy” rating on the stock. HC Wainwright’s price target would indicate a potential upside of 279.75% from the company’s previous close.

A number of other research analysts also recently commented on the company. Zacks Investment Research downgraded IntelliPharmaCeutics Intl from a “hold” rating to a “sell” rating in a research note on Wednesday, January 17th. Maxim Group set a $2.00 target price on IntelliPharmaCeutics Intl and gave the company a “buy” rating in a research note on Friday. Two analysts have rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the company’s stock. IntelliPharmaCeutics Intl currently has an average rating of “Hold” and a consensus target price of $2.53.

IntelliPharmaCeutics Intl (NASDAQ IPCI) traded up $0.04 during trading hours on Monday, reaching $0.79. The company had a trading volume of 148,979 shares, compared to its average volume of 534,710. The firm has a market capitalization of $23.30, a price-to-earnings ratio of -2.25 and a beta of 1.06. IntelliPharmaCeutics Intl has a 52-week low of $0.70 and a 52-week high of $2.92.

An institutional investor recently raised its position in IntelliPharmaCeutics Intl stock. Advisor Group Inc. lifted its stake in shares of IntelliPharmaCeutics Intl Inc (NASDAQ:IPCI) (TSE:I) by 57.7% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 47,409 shares of the company’s stock after acquiring an additional 17,342 shares during the quarter. Advisor Group Inc. owned about 0.16% of IntelliPharmaCeutics Intl worth $100,000 as of its most recent filing with the SEC. 3.28% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: This report was originally published by American Banking News and is the sole property of of American Banking News. If you are reading this report on another website, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright legislation. The legal version of this report can be read at https://www.americanbankingnews.com/2018/02/12/intellipharmaceutics-intl-ipci-given-a-3-00-price-target-at-hc-wainwright.html.

IntelliPharmaCeutics Intl Company Profile

Intellipharmaceutics International Inc is a Canada-based pharmaceutical company engaged in the research, development and manufacture of controlled-release and targeted-release oral solid dosage drugs. Its Hypermatrix technology is a multidimensional controlled-release drug delivery platform that is applied to the development of a range of existing and new pharmaceuticals.

Receive News & Ratings for IntelliPharmaCeutics Intl Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IntelliPharmaCeutics Intl and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply